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Abstract
Background: Many tumours undergo disregulation of polyamine homeostasis and upregulation of
ornithine decarboxylase (ODC) activity, which can promote carcinogenesis. In animal models of
colon carcinogenesis, inhibition of ODC activity by difluoromethylornithine (DFMO) has been
shown to reduce the number and size of colon adenomas and carcinomas. Indole-3-carbinol (I3C)
has shown promising chemopreventive activity against a range of human tumour cell types, but little
is known about the effect of this agent on colon cell lines. Here, we investigated whether inhibition
of ODC by I3C could contribute to a chemopreventive effect in colon cell lines.
Methods: Cell cycle progression and induction of apoptosis were assessed by flow cytometry.
Ornithine decarboxylase activity was determined by liberation of CO2 from 14C-labelled substrate,
and polyamine levels were measured by HPLC.
Results: I3C inhibited proliferation of the human colon tumour cell lines HT29 and SW480, and
of the normal tissue-derived HCEC line, and at higher concentrations induced apoptosis in SW480
cells. The agent also caused a decrease in ODC activity in a dose-dependent manner. While
administration of exogenous putrescine reversed the growth-inhibitory effect of DFMO, it did not
reverse the growth-inhibition following an I3C treatment, and in the case of the SW480 cell line,
the effect was actually enhanced. In this cell line, combination treatment caused a slight increase in
the proportion of cells in the G2/M phase of the cell cycle, and increased the proportion of cells
undergoing necrosis, but did not predispose cells to apoptosis. Indole-3-carbinol also caused an
increase in intracellular spermine levels, which was not modulated by putrescine co-administration.
Conclusion: While indole-3-carbinol decreased ornithine decarboxylase activity in the colon cell
lines, it appears unlikely that this constitutes a major mechanism by which the agent exerts its
antiproliferative effect, although accumulation of spermine may cause cytotoxicity and contribute
to cell death. The precise mechanism by which putrescine enhances the growth inhibitory effect of
the agent remains to be elucidated, but does result in cells undergoing necrosis, possibly following
accumulation in the G2/M phase of the cell cycle.
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Background
There is strong epidemiological evidence to support a pro-
tective role of fruit and vegetables against the develop-
ment of cancer in a range of major organs, in particular of
the breast and the digestive tract. This evidence has led to
the isolation and characterisation of discreet dietary con-
stituents that may be responsible for their chemopreven-
tive activity. I3C is derived from cruciferous vegetables
such as broccoli and Brussels sprouts, and possesses anti-
carcinogenic activity in a number of models, both in vivo
and in vitro. It has received considerable attention as a po-
tential anti-tumour agent for breast cancer, particularly
due to its ability to alter the estrogen metabolite ratio of
2-hydroxyestrone to 16-α-hydroxyestrone [1–3], and has
recently been the subject of a breast cancer prevention
dose-finding pilot study using the urinary estrogen metab-
olite ratio as the surrogate endpoint biomarker [4]. Prom-
ising results have been obtained in phase I clinical trials of
I3C against recurrent respiratory papillomatosis or cervi-
cal intraepithelial neoplasia [5,6].
I3C has also been shown to protect against carcinogen-in-
duced tumours in a range of rodent models including liv-
er, tongue, skin, mammary tissue and colon [7–12]. Some
studies however, have suggested that when administered
after chemically-induced initiation, I3C may have pro-
moting activity in liver, raising concerns as to its suitabil-
ity for use as a chemopreventive agent in humans [12–
15]. The latter two of these studies showed that in medi-
um and long-term treatment protocols (10 and 30 weeks
respectively), I3C increased glutathione S-transferase-P
(GST-P) positive foci in livers of rats initiated with diethyl-
nitrosamine [15], or in a multi-organ rat model initiated
with 7,12-Dimethylbenz [a]anthracene plus azoxymeth-
ane plus AFB1 [12], and these results were interpreted as
indicating a promoting effect of I3C on hepatocarcino-
genesis. In a long-term (48 week) feeding study we
showed that I3C prevented aflatoxin B1 (AFB1)-induced
liver carcinogenesis in Fisher F344 rats, irrespective of
whether it was administered before or after the carcinogen
[7]. Interestingly, at an earlier time point in our feeding
study (13 weeks) we observed strong focal liver staining
for γ-glutamyl transpeptidase and GST-P in rats treated
with I3C post-initiation. Using these criteria alone as pre-
dictors of tumourigenesis, we would have expected no ef-
fect, or indeed an increase in tumours in the livers of these
animals. However this was not the case, and at 48 weeks
the animals treated with I3C following AFB1 were com-
pletely protected [7]. While the mechanism by which I3C
exerts tumour blocking activity has been attributed to the
induction of drug metabolising enzymes, which can lead
to increased conjugation and excretion of the carcinogen
and decreased DNA adduct formation [16–23], the mech-
anisms by which it suppresses tumour promotion and
progression are not well defined.
Inhibition of ornithine decarboxylase (ODC) activity has
been proposed as a target mechanism for tumour suppres-
sion, reviewed by Pegg [24]. ODC is the rate-limiting en-
zyme in the biosynthesis of polyamines, which are
required for normal cell proliferation. Polyamine levels
and ODC activity are elevated in a wide range of tumours,
and high levels correlate with poor prognosis in breast
cancer patients [25–27]. ODC has further been implicated
in the carcinogenic process by findings that overexpres-
sion promotes tumourigenesis in vivo, and can be suffi-
cient for transformation of cell lines in vitro [28–31].
Therefore inhibition of ODC activity has been commonly
used as a predictor of chemopreventive activity, and as an
intermediate endpoint biomarker of clinical efficacy in in-
tervention studies. The regulation of ODC activity within
the cell is complex, and occurs at a multitude of levels,
[32–34], including protein degradation, post-translation-
al modification, mRNA translation and gene transcrip-
tion. ODC protein levels are regulated by antizyme, which
binds to, and targets ODC for degradation by the 26S pro-
teasome, reviewed in [35]. ODC is also heavily regulated
at the level of mRNA translation due to secondary struc-
ture in the 5' untranslated region, which can be modified
by activity of the translation initiation factor eIF-4E
[32,36]. The ODC promoter has been shown in various
species to be regulated by a number of transcription fac-
tors, including the Wilms' tumour suppressor WT1 [37–
40] and references therein. ODC activity can also be mod-
ulated in response to many signalling pathways including
the epidermal growth factor receptor, phospho-inositide
3-kinase (PI3K), and estrogen receptor pathways [41–44].
In the long term feeding study mentioned above [7], the
level of ODC activity in livers of rats which received die-
tary I3C was markedly decreased compared to that in rats
on a control diet. The current study was designed to ex-
plore whether alteration of ODC activity and polyamine
levels might play a mechanistic role in the chemopreven-
tive efficacy of I3C in colon cells. To that end the effects of
I3C on cell growth, ODC activity and intracellular
polyamine levels were studied in human-derived colon
cancer cells.
Difluoromethylornithine (DFMO) is a well-studied spe-
cific inhibitor of ODC enzyme activity. Initial trials of
DFMO as a cancer therapeutic agent were disappointing,
showing dose-limiting toxicity, together with little thera-
peutic activity. The contents of the intestinal and colonic
lumen form a rich supply of polyamines, augmented by
dietary sources and intestinal bacteria [45–49]. Exoge-
nous polyamines are rapidly taken up by polyamine-de-
pleted cells, and can be utilised for tumour growth [50],
offering one explanation for the apparent lack of activity
of DFMO in humans. However, more recently, DFMO hasBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/2
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attracted much interest as a potential chemopreventive
agent at lower doses [51–58].
In order to determine any similarity in mechanism of che-
mopreventive activity between I3C and DFMO the modu-
lation of the growth inhibitory effects of the two agents by
polyamines was investigated.
Methods
Cell lines and treatments
Immortalized human colon epithelial cells (HCEC) and
human-derived colon carcinoma cell lines SW480 and
HT29 were kindly provided by A. Pfeifer (Nestec Ltd.,
Lausanne, Switzerland) and C. Paraskeva (Bristol Univer-
sity, UK), respectively, and were cultured as described pre-
viously [59,60]. All cell lines tested negative for
mycoplasma infection and were cultured without antibi-
otics. I3C (Sigma-Aldrich Company Ltd.; Poole, UK) was
prepared as a stock solution in DMSO, and cells were
treated in such a way that all control and treated cells re-
ceived equal volumes of DMSO, which did not exceed a fi-
nal concentration of 0.05%. For each experiment, cells
were seeded in normal growth medium and were allowed
to adhere for at least 4 hours before treatment. Cells were
treated with concentrations of I3C from 100 µM up to 1
mM in some experiments. It should be noted that any ef-
fects seen at concentrations above 500 µM are unlikely to
be physiologically relevant. All cell culture reagents (GIB-
CO) were purchased from Invitrogen Ltd. (Paisley, UK).
Cell growth assays
Cells were seeded at 1 × 104 onto 24 well plates in normal
growth medium, and allowed to adhere, prior to treat-
ment with I3C for times up to 10 days. The culture medi-
um was not changed during the incubation time. Cells
were harvested by trypsinisation at 24 hourly intervals
and counted on a Coulter ZM electronic cell counter
(Beckman Coulter UK Ltd., High Wycombe, UK).
Mean IC50 values were obtained from plots of cell number
expressed as a percentage of control, versus I3C concentra-
tion following treatment for 7 days. In further growth ex-
periments, HT29 and SW480 cells were treated with
concentrations of I3C (250 or 175 µM respectively), or
DFMO (125 or 50 µM; CN Biosciences (UK) Ltd., Beeston,
UK), and cultured for 7 days in the presence or absence of
putrescine as indicated. To determine their ability to re-
cover proliferative capacity following treatment, cells (1 ×
104 on 12 well plates) were cultured in the presence of
I3C, plus or minus putrescine, for 24 hours, after which
they were either maintained in treated medium or washed
and replenished with fresh medium and allowed to recov-
er before harvesting on day 7. The proliferation rate of
cells was calculated as fold increase in cell number follow-
ing the initial treatment period.
For analysis of cell cycle, 5 × 105 cells were seeded onto 9
cm plates and treated with I3C in the presence or absence
of putrescine for 96 hours. Cells were harvested by
trypsinisation and fixed overnight in 70% ethanol at 4°C,
then collected by centrifugation and resuspended in PBS
containing 0.1 mg/ml RNase and 5 µg/ml propidium io-
dide and incubated overnight at 4°C. DNA content was
analysed using a Becton Dickinson FACScan and Cell
Quest software, plotting 5000 events per sample. Subse-
quent data analysis was performed using ModFit LT soft-
ware (Becton Dickinson UK Ltd.; Cowley, UK).
Measurement of phosphatidylserine externalisation
Cells were seeded at 2–5 × 105 onto 9 cm plates and treat-
ed with I3C for 96 hours. After treatment, cells obtained
by trypsinisation were combined with those that had
spontaneously detached during the incubation. Phos-
phatidylserine externalisation was determined by annexin
V staining. Cells were pelleted and resuspended in 1 ml
annexin buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 5
mM KCl, 1 mM MgCl2, 1.8 mM CaCl2). FITC-conjugated
annexin V was added to a final concentration of 100 ng/
ml and cells were incubated for 8 min at room tempera-
ture, after which propidium iodide (1.5 µg) was added
and cells were analysed by flow cytometry using a FACS-
can flow cytometer (Becton Dickinson, San Jose, CA) and
Cell Quest software.
Measurement of ODC activity
Colon cells were seeded at 5 × 105 onto 9 cm plates and
allowed to adhere prior to treatment with I3C for 24
hours. Whole cell lysates were prepared by successive
rounds of freeze thawing of cells suspended in 200 µl so-
dium phosphate buffer (100 mM, pH 7.2). ODC activity
in cell lysates (90 µl) was determined by measurement of
14CO2 released from labelled ornithine, under reaction
conditions described previously [7]. Protein content of
cell lysates was determined using the BioRad protein assay
kit (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK).
ODC activity was calculated as pmol CO2 produced/ mg
protein/ hour, and results are expressed as a percentage of
activity in control samples (DMSO-treated).
Measurement of intracellular polyamine levels
Cells seeded onto 9 cm plates at densities between 5 × 105
and 2 × 106 depending on treatment time, were treated
with I3C in the presence or absence of putrescine for 24,
96 or 168 hours, and were then harvested and washed
twice with PBS. Cell pellets were resuspended in 200 µl
10% trichloroacetic acid, and the acid-soluble polyamines
extracted by centrifugation. Dansylated polyamines were
detected by fluorescence, following separation by ion-
pairing reversed phase HPLC. Dansylation and extraction
of polyamines was based on published methods [61,62].
In brief, extracts were mixed with 400 µl dansyl chlorideBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/2
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Figure 1
Inhibition of cell growth by I3C. Cells were treated with I3C and counted at 24 hourly intervals as described in Materials 
and Methods. Results are presented as mean ± SEM (n = 6), * indicates significant difference from control cell numbers at that 
time point (P < 0.05).
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(5 mg/ml in acetone) in the presence of approximately
300 mg solid sodium carbonate, together with 500 nmol
of the internal standard 1,6-hexanediamine, and incubat-
ed for 20 min at 70°C. Reactions were allowed to cool to
room temperature and excess dansyl chloride was seques-
tered by the addition of 200 µl proline (250 mg/ml).
Polyamines were then extracted into 4 ml cyclohexane,
and following evaporation of the cyclohexane were recon-
stituted in 200 µl acetonitrile. Dansylated polyamines
were separated and detected using a Gilson 715 series
HPLC system with a BDS C18 column (250 × 4.6 mm,
particle size 3 µm, Hypersil, Runcorn, UK) coupled to a
Waters 470 scanning fluorescence detector (excitation 336
nm, emission 520 nm). The mobile phase consisted of a
gradient between buffer A (0.02 M 1-heptanesulphonic
acid (pH 3.4), acetonitrile, methanol (5:3:2 v/v)) and
buffer B (acetonitrile, methanol (3:2 v/v)) essentially as
described by Aboul-Enein and Al-Duraibi [63].
Measurement of putrescine uptake
SW480 cells were seeded at 5 × 104 onto 24 well plates,
and treated with I3C (0–500 µM) or DFMO (50 µM) in 1
ml medium for 24 hours. Cells were then treated with 10
µl 10 mM putrescine containing 0.25 µCi 14C-labelled pu-
trescine, and incubated for a further 30 min prior to termi-
nation of the experiment. Cells were then washed
thoroughly with 1 mM putrescine, and lysed in 250 µl 1
M NaOH 60°C for 1 hour. The lysate was neutralised with
250 µl 1 M HCl, and 14C-labelled putrescine that had
been incorporated into the cells was determined by scin-
tillation counting. Protein content of the lysates was deter-
mined using the BioRad protein assay reagent.
Measurement of intracellular glutathione
Cells were seeded at 5 × 104 to 1 × 106 onto 6 well plates
(according to treatment time) and treated with I3C in the
presence or absence of putrescine for 24, 96 or 168 hours.
Cells were harvested by trypsinisation and intracellular
glutathione levels were determined according to the
method of Baker et al. [64].
Statistical analysis
Data were analysed by ANOVA using either Oneway anal-
ysis followed by Tukey's posthoc test, or the General Lin-
ear Model twoway analysis followed by Fisher's Least
Significant Difference test, as appropriate [65,66].
Results
Effect of I3C on proliferation and ODC activity of colon 
cell lines
I3C inhibited proliferation of the two tumour-derived co-
lon cell lines SW480 and HT29, and of the normal-de-
rived HCEC cell line (Fig 1). The IC50s (mean ± SD, n = 3;
168 hr) for the SW480, HT29 and HCEC cell lines were
calculated as 123.22 ± 8.87; 127.20 ± 8.13 and 164.5 ± 7.0
µM respectively. These values are consistent with concen-
trations reported to exert biological activity in a range of
other cell lines [67–70]. The basal level of ODC activity
was low in the normal-derived HCEC line, 156.1 ± 9.3
pmol CO2 produced/ hour/ mg protein, while levels were
found to vary markedly between the two tumour cell
lines. The HT29 line showed high activity, 1079.0 ± 42.4,
while the SW480 line exhibited activity of 171.3 ± 20.9
pmol CO2 produced/ hour/ mg protein. The SW480 cell
line is unusual in this respect, as tumour derived cell lines
commonly exhibit high levels of ODC activity. I3C de-
creased basal ODC activity in a dose-dependent manner
in all three colon cell lines after treatment for 24 hours
(Fig 2), with the HCEC line showing greatest sensitivity,
and the SW480 line showing least inhibition. I3C did not
inhibit ODC activity when the agent was added directly
into an assay (data not shown), indicating that the agent
does not act as a direct enzyme inhibitor. Interestingly, the
HCEC cell line showed the least decrease in cell number
in response to I3C at this time point. This lack of apparent
cytotoxicity is in agreement with a recent study by Bon-
nesen et al. [71], which reported an IC50 in excess of 500
µM I3C in this cell line using MTT tests carried out after 24
hours.
Effect of exogenous putrescine on growth modulation by 
DFMO and I3C
To determine the extent to which inhibition of ODC activ-
ity contributed to the antiproliferative activity of I3C in
the tumour lines, we made a comparison of its growth in-
hibitory effect with that of the specific ODC inhibitor, and
known antitumour agent, DFMO. The growth inhibitory
action of DFMO can be reversed by exogenously added
putrescine, which restores intracellular levels of
polyamines required for cell proliferation. In all three cell
lines, supplementation of culture medium with pu-
trescine reversed the effects of DFMO as expected, and in
agreement with data obtained for the HT29 cell line by
Gamet et al. [72]. We hypothesised therefore that if the
growth-inhibitory effect of I3C was directly related to its
ability to decrease ODC activity, then as for DFMO, this
may be reversed by supplementation with putrescine. In-
terestingly, putrescine did not reverse the inhibitory effect
caused by I3C in any of the colon cell lines, and at concen-
trations that did not affect control cell growth (5–100
µM), it actually increased growth inhibition of I3C-treated
SW480 cells in a dose-dependent manner (Fig. 3; p <
0.05). This cell line was also found to be particularly sen-
sitive to exogenously added putrescine, with concentra-
tions in excess of 100 µM inhibiting proliferation of
control cells. In contrast, the HT29 and HCEC cell lines
were resistant to concentrations of exogenous putrescine
up to 500 µM, whether cultured with or without I3C.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/2
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Figure 2
Effect of I3C on basal ODC activity and cell number after 24 hours. ODC activity in cell lysates was determined as 
described in Materials and Methods. Results are expressed as a percentage of control values (n = minimum of 5; pooled SD of 
each set for ODC activity and cell number for each cell line are: SW480, 18.76, 11.38; HT29, 13.12, 4.11; HCEC, 15.22, 12.37 
respectively). Significant difference from the control (DMSO treated) is indicated by * (P < 0.05).
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Figure 3
Effect of putrescine supplementation on cell growth inhibition by I3C and DFMO. Cells were treated with I3C 
(SW480 175 µM; HT29 250 µM; HCEC 180 µM) or DFMO (SW480 50 µM; HT29 and HCEC 125 µM) or DMSO (control) and 
cultured in the presence or absence of putrescine (5–500 µM) for 7 days and then counted as described in Materials and Meth-
ods. Results are mean ± SD (n = 4), a indicates bars which are significantly different from control (DMSO without putrescine) 
group, b indicates significant difference from the I3C alone treatment, and c indicates significant difference from the DFMO 
alone treatment (P < 0.05).
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The cell lines also differed in their ability to recover from
treatment with I3C (Fig 4). The HT29 cell line recovered
completely from 24 hour treatment with I3C up to 500
µM, and also recovered from combined I3C (250 µM)/
putrescine (500 µM) treatment. In contrast, SW480 cells
only partially recovered from 24 hour treatment with I3C
at 175 µM in the presence or absence of putrescine (50
µM), and were unable to recover from higher concentra-
tions of I3C. The HCEC cell line behaved more like the
HT29 line, but did not recover completely. The reason for
this apparent difference in the ability of the two tumour
cell lines to recover from treatment is not clear at the
present time. However, these data may suggest that I3C
could be acting via different mechanisms, one reversible
and one irreversible; alternatively, it is also possible that
the effect is time dependent and that treatment with I3C
for a longer period would have resulted in irreversible
growth inhibition in the HT29 cell line also. We have pre-
viously observed a difference in the ability of two breast
cell lines, HBL100 and MDA MB468 to recover from I3C
treatment [67], which we concluded was related to the in-
duction of apoptosis in the latter, but not in the former
cell line.
Effect of I3C and exogenous putrescine on induction of ap-
optosis or cell cycle arrest
In order to investigate whether I3C induces apoptosis in
colon cells, and to address the possibility that the combi-
nation treatment of I3C plus putrescine may predispose
SW480 cells to apoptosis, we compared levels of live, ap-
optotic and necrotic cells, determined by measurement of
phosphatidylserine externalisation after treatment with
I3C alone, I3C plus putrescine, or DFMO.
Treatment with I3C caused significant induction of apop-
tosis in the SW480 cell line at 250 and 500 µM after 96
hour treatment, but only slight induction was apparent
with 175 µM (Fig 5). Induction of apoptosis was accom-
panied by an increase in necrotic cells, possibly due to sec-
ondary necrosis of previously apoptotic cells. It seems
unlikely that the low level of apoptosis seen in response
to 175 µM I3C after 96 hours could account for the appar-
ently irreversible nature of growth inhibition observed for
this concentration in the SW480 cell line.
The combination treatment did not further induce apop-
tosis, but did cause a significant increase in the proportion
of cells undergoing necrosis (9.5% in the I3C + putrescine
treatment compared with 4% for I3C 175 µM alone; P <
0.05). The effect of combination of putrescine with higher
concentrations of I3C (250 or 500 µM) was not assessed
due to the high level of toxicity encountered with the orig-
inal combination treatment (I3C 175 µM + putrescine).
Putrescine alone had no effect on control cells. DFMO did
not induce apoptosis or necrosis following treatment for
96 hours (data not shown).
We also investigated whether cell cycle arrest may contrib-
ute to the inhibition of cell growth at these concentra-
tions. DFMO caused an increase in the proportion of cells
in G0/G1 phase of the cell cycle in both tumour cell lines,
as has been previously reported in other cell lines [73–
75]. No major phase specific block in cell cycle progres-
sion was observed following treatment with I3C alone or
in combination with putrescine for 96 hours in either cell
line. However, I3C caused a small but significant decrease
in G0/G1, which was accompanied by an increase in the
proportion of cells in G2/M in the SW480 cell line. Accu-
mulation of cells in G2/M achieved significance in the I3C
+ putrescine treatment compared with control SW480
cells, but was not significantly elevated above levels of I3C
treated cells (Fig. 6A). In order to further investigate this
effect, cells were first synchronised in G2/M by treatment
with nocodazole, and then released into either control or
I3C ± putrescine-treated medium. Neither I3C alone, nor
in combination with putrescine caused a delay in exit of
cells from G2/M, however, cells in both treatment groups
appeared to accumulate in G2/M by 32 hours after release
(Fig 6B). The agents did not prolong progression of cells
through any phase of the cycle within 24 hours of release
from nocodazole block.
Modulation by I3C of intracellular polyamines and effect 
of exogenous putrescine in SW480 cells
To investigate whether modulation of intracellular
polyamine levels could be contributing to the sensitisa-
tion of the SW480 cells to I3C by putrescine, intracellular
putrescine, spermidine and spermine levels were meas-
ured after treatment with I3C in the presence or absence
of putrescine. In control cells at the 24 hour time point,
spermine was the most abundant of the polyamines ana-
lysed, occurring at levels approximately 1.5 and 4 fold
higher than spermidine and putrescine respectively. Expo-
sure to I3C for 24 hr resulted in a significant decrease in
intracellular putrescine levels, which was completely re-
versed by co-exposure of the cells to exogenous putrescine
(Fig 7; Table 1). The I3C-induced decrease was transient,
as by 96 hours of treatment, intracellular putrescine was
found to be slightly raised above control levels. Levels of
spermidine were not consistently altered at any time point
during exposure to I3C (Table 1). In contrast, at each time
point, levels of intracellular spermine were increased in
cells treated with I3C concentrations that caused a de-
crease in cell number (Fig. 8), indicating a possible inverse
relationship between spermine accumulation and cell
growth. While co-administration of exogenous putrescine
restored intracellular putrescine levels to normal, it did
not alter intracellular levels of spermine in control cells, or
prevent the accumulation of spermine in I3C-treated cellsBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/2
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Figure 4
Recovery of cells from 24 hour treatment with I3C. Cells were cultured in the presence of I3C for 24 hours, after 
which cells were either maintained in I3C-containing medium or replenished with fresh medium and allowed to recover, as 
described in Materials and Methods. Cell proliferation is expressed as a % of the control values, data are presented as mean ± 
pooled SD (shown on control bar only; n = 3). Significant difference from the control (DMSO treated) is indicated by * (P < 
0.05).
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(data not shown). The total intracellular level of the three
polyamines was also increased in response to I3C, in a
pattern corresponding with that of the major component,
spermine.
In a preliminary experiment (assays performed in dupli-
cate) intracellular levels of GSH were determined in ex-
tracts from cells treated for either 24, 96 or 168 hours. No
evidence for a decrease in GSH level was obtained with
any treatment at any of the time points (data not shown).
Effect of I3C on uptake of putrescine by SW480 cells
In order to further investigate the effect of I3C on regula-
tion of the intracellular putrescine pool, we determined
putrescine uptake following treatment with I3C alone or
in medium supplemented with putrescine. SW480 cells
which had been treated with I3C under normal growth
conditions for 24 hours exhibited a 50% decrease in the
rate of putrescine uptake (Fig 9), which appeared to corre-
late with the decrease in intracellular putrescine levels
shown in Fig 7. DFMO increased the rate of putrescine up-
take 2.5-fold over control levels (Fig 9).
Discussion
Upregulation of ODC has been implicated as a necessary
and early step in carcinogenesis. The ability of some che-
mopreventive agents, such as DFMO, to inhibit ODC ac-
tivity is therefore thought to be an important mechanistic
Figure 5
Induction of apoptosis or necrosis in SW480 cells by I3C in the presence or absence of putrescine. Cells were 
treated for 96 hours and then harvested and stained for phosphatidylserine externalisation and propidium iodide incorporation 
before analysis by flow cytometry as described in Materials and Methods. Control = DMSO treated cells, C+P = DMSO plus 
putrescine (50 µM), I175, I250, I500 = I3C (at the given concentration) and I+P = I3C (175 µM) plus putrescine. Significant dif-
ference from control is indicated by a, and between the I3C 175 µM and I3C + putrescine treatment by b (P < 0.05). Results are 
displayed as means (n = 12), pooled SD = 6.08.
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Figure 6
Effect of I3C in the presence or absence of putrescine on progression of SW480 cells through the cell cycle. A) 
Cells were treated for 96 hours as indicated, and stained with propidium iodide before analysis by flow cytometry as described 
in Materials and Methods. Control = DMSO treated cells, C+P = DMSO plus putrescine (50 µM), I3C = I3C (175 µM) and I+P 
= I3C (175 µM) plus putrescine, DFMO = DFMO (50 µM). * indicates a significant difference from control levels (P < 0.05; n = 
8; pooled SD = 3.54). B) Cells were synchronised with nocodazole for 24 hr (Noc (24 hr)) and then released into control (Con 
+32 hr), I3C (I3C +32 hr) or I+P (I+P +32 hr) treated medium and analysed as described in Materials and Methods. Data from 
the +32 hr time point is shown. Control = DMSO treated, non-synchronised cells. * indicates a significant difference from the 
Con +32 hr value for each phase of the cell cycle (P < 0.05; n = 4; pooled SD = 2.61).
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Figure 7
Effect of I3C in the presence or absence of putrescine on intracellular putrescine levels in SW480 cells follow-
ing 24 hour treatment. Cells were cultured with DMSO alone (Control) or I3C (175 µM) in the presence of 0, 20 or 50 µM 
putrescine as indicated. Intracellular putrescine levels were determined by HPLC, as described in Materials and Methods. 
Results are presented as mean ± pooled SD (shown on control bar only, n = 4). nd = value not determined. Significant differ-
ence from the control (DMSO without putrescine), and from I3C without putrescine, is indicated by a and b respectively (P < 
0.05).
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Figure 8
Effect of I3C on cell number and intracellular spermine levels in SW480 cells after 24, 96 or 168 hour treat-
ments. Cells were treated with DMSO alone (Con) or I3C as indicated, and intracellular spermine levels were determined by 
HPLC, as described in Materials and Methods. Results are presented as percentage of control values (mean n = 4; * indicates 
significant difference from control levels (P < 0.05); pooled SD = 0.8, 0.6, 1.1 and 24.4, 11.8, 12.0 for spermine levels and cell 
numbers respectively at 24, 96 and 168 hours). The mean spermine concentration (nmol/106 cells) in control cells at 24, 96 and 
168 hr was 2.10, 1.25 and 0.76 respectively.
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contributor to their anticarcinogenicity. The results de-
scribed above show for the first time that in colon cancer
cells I3C decreases ODC activity and interferes with intra-
cellular polyamine levels. However, there are intriguing
differences between I3C and the classical ODC inhibitor,
DFMO. Consistent with the known mechanism of action
of DFMO, exogenously added putrescine antagonised
growth inhibition caused by this agent. In contrast, while
I3C also reduced ODC activity and decreased intracellular
putrescine levels, its growth-inhibitory effect was not re-
versed, and in the case of the SW480 cell line, was actually
increased in the presence of exogenous putrescine. This
led us to conclude that in the colon tumour cells studied
here, the growth inhibitory effect of I3C appeared to be in-
dependent of its ability to decrease intracellular pu-
trescine levels. This conclusion is further supported by the
observation that exogenously added putrescine restored
intracellular putrescine levels of I3C-treated cells to nor-
mal. It is worthy of note, that while exogenously added
putrescine can reverse growth inhibition due to impaired
polyamine synthesis, it cannot reverse growth inhibition
caused by altered polyamine catabolism or efflux.
It is possible that the decrease in putrescine observed at
the initial time point, was not wholly due to inhibition of
ODC activity or decreased uptake, but also due to the con-
tinued conversion of the diamine to spermidine, levels of
which did not fall in response to I3C treatment. Pu-
trescine levels in SW480 cells were also found to have re-
verted to control levels after 96 hours of treatment with
I3C alone indicating that the cells overcome these initial
effects of I3C observed at 24 hours. Several possibilities
may account for this, including reversal of the inhibition
of ODC activity and/or putrescine uptake observed after
24 hour treatment. I3C treatment of SW480 cells resulted
in an accumulation of intracellular spermine over time
(up to approximately 5 fold above control levels), which
Table 1: Effect of I3C alone and in combination with putrescine on intracellular polyamine levels at 24, 96 and 168 hours.
Treatment Cell no. as % Control (SD) Putrescine (SD) Spermidine (SD) Spermine (SD)
24 hour
Control 100.0 (0.0) 0.48 (0.31) 1.62 (0.55) 2.10 (0.98)
I3C 100 89.1 (19.8) 0.31 (0.09) 1.79 (0.51) 2.25 (1.21)
I3C 175 87.9 (29.2) 0.23 (0.06)* 1.32 (0.36) 1.54 (0.19)
I3C 250 77.4 (32.7) 0.19 (0.04)* 2.17 (0.98) 2.73 (1.86)
I3C 500 54.2 (26.6) 0.14 (0.07)* 1.57 (0.60) 2.74 (1.82)
C + P20 96.9 (23.5) 0.64 (0.26) 2.17 (1.06) 2.41 (1.53)
C + P50 90.0 (42.1) 0.72 (0.27)* 2.34 (1.48) 2.59 (1.93)
I + P20 76.2 (26.3) 0.69 (0.29) 2.93 (1.57)* 3.06 (1.99)
I + P50 76.1 (35.0) 0.54 (0.16) 1.86 (0.49) 1.94 (0.65)
96 hour
Control 100.0 (0.0) 0.08 (0.04) 0.79 (0.30) 1.25 (0.38)
I3C 100 98.7 (8.5) 0.13 (0.09) 1.11 (0.40) 1.87 (0.47)
I3C 175 58.9 (3.8) 0.13 (0.10) 0.98 (0.29) 2.18 (0.79)*
I3C 250 24.9 (6.1) 0.15 (0.11) 0.77 (0.36) 2.03 (1.17)*
I3C 500 13.9 (6.0) nd 0.62 (0.32) 1.34 (0.45)
C + P20 96.6 (12.4) 0.13 (0.03) 0.84 (0.15) 1.15 (0.12)
C + P50 79.2 (14.3) 0.32 (0.18)* 1.47 (0.15)* 1.98 (0.34)
I + P20 28.1 (22.6) 0.17 (0.09) 1.25 (0.23)* 2.42 (0.21)*
I + P50 17.9 (2.9) 0.11 (0.02) 0.80 (0.21) 1.54 (0.48)
168 hour
Control 100.0 (0.0) 0.04 (0.02) 0.46 (0.07) 0.76 (0.17)
I3C 100 104.0 (9.9) 0.03 (0.01) 0.57 (0.25) 1.22 (0.32)
I3C 175 57.1 (9.5) 0.05 (0.03) 0.62 (0.28) 1.99 (0.96)*
I3C 250 31.1 (20.2) 0.07 (0.01) 0.87 (0.54) 2.93 (0.72)*
I3C 500 4.5 (5.2) nd nd nd
C + P20 107.2 (4.8) 0.03 (0.01) 0.48 (0.04) 0.83 (0.15)
C + P50 104.5 (10.1) 0.06 (0.04) 0.67 (0.10) 1.08 (0.19)
I + P20 6.0 (5.5) nd 0.91 (0.55) 3.11 (1.59)*
I + P50 3.0 (0.7) nd 0.90 (0.56) 2.26 (1.42)*
Cells were treated with I3C alone or in combination with putrescine, and intracellular polyamines determined as described in the Methods Section. 
Data shown for cell numbers are expressed as a % Control, and polyamine levels are nmol/106 cells. All values are means with SD in brackets. nd = 
values not determined. * indicates a value that is significantly different to the control value at that time point.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/2
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corresponded with a dose dependent decrease in cell
number at each time point.
There are many reports in the literature detailing the cyto-
toxic effects of spermine [76–81], although it should be
noted that high concentrations of exogenous spermine
were used in these studies. It is possible that the accumu-
lation of spermine seen in response to treatment with I3C
contributes to its growth-inhibitory action in this cell line.
Addition of exogenous putrescine, did not prevent (nor
significantly increase), the accumulation of intracellular
spermine levels observed in response to treatment with
I3C, which may explain, at least in part, the inability of ex-
ogenous putrescine to prevent the I3C-induced growth in-
hibition. Several mechanisms have been proposed for the
cytotoxicity of spermine, including competition for sper-
midine and Mg2+ binding sites, thus preventing many of
the physiological functions of spermidine and Mg2+, such
as protein synthesis, as well as loss of intracellular glutath-
ione through conjugation or spermine-induced oxidative
stress, or a direct toxic effect of the spermine itself
[78,80,81]. In preliminary experiments we found no evi-
dence of a decrease in intracellular GSH levels following
any treatment.
Seiler et al. [76] have reported a non-apoptotic mecha-
nism of cell death in CaCo-2 cells that had accumulated
high levels of spermine (more than double normal lev-
Figure 9
Effect of I3C on putrescine uptake in SW480 cells. Cells were treated with DMSO alone (Con), I3C or DFMO as indi-
cated, and putrescine uptake determined as described in Materials and Methods. Results are presented as percentage of con-
trol values (n = minimum of 4) * indicates significant difference from control levels (P < 0.05).
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els). In that study, exposure to 5 mM spermine caused a
decrease in the population of cells in G1, and an accumu-
lation in the G2 phase of the cell cycle [76]. In our study,
at higher concentrations (≥ 250 µM), I3C caused induc-
tion of apoptosis accompanied by necrosis, but only a
small increase in either was observed at the 96 hour time
point with 175 µM I3C, and although we did not obtain a
clear phase specific arrest with any treatment in our study,
the proportion of cells in G1 decreased and the number in
G2/M increased in response to I3C from 32 hours. In the
combination treatment (I3C + putrescine), the number of
cells in G2/M was slightly increased and the proportion of
cells undergoing necrosis was significantly increased com-
pared with I3C treatment alone. Although each of these
changes appears to be small when considered in isolation,
in combination they may be sufficient to account for the
inhibition caused by I3C in the cell growth experiments.
At 96 hr, control cells showed combined apoptosis +
necrosis of less than 4%, with approximately 8% of cells
in G2/M; I3C (175 µM)-treated cells showed combined
apoptotic and necrotic cells of 9%, with 11% in G2/M,
while of I3C + putrescine-treated cells, approximately
16% were undergoing apoptosis or necrosis, with 13% in
G2/M.
The mechanism by which I3C inhibited ODC activity was
not further investigated in this study, but clearly occurs at
a level distinct from the direct enzyme inhibition caused
by DFMO. ODC activity can be regulated via many signal-
ling pathways, including the epidermal growth factor re-
ceptor, PI3K, and estrogen receptor pathways [41–44],
which are potential targets for the action of chemopreven-
tive agents such as I3C. We have shown, for example, that
I3C can inhibit the PI3K/ protein kinase B pathway in the
MDA MB468 breast tumour cell line, but not in the nor-
mal derived HBL100 line [67], but this did not correlate
with the ability of this agent to inhibit ODC activity in
those cell lines (Howells L.M. et al. unpublished data).
There are clearly multiple possible mechanisms via which
I3C could exert its effect on ODC activity in these colon
cell lines, including inhibition of signalling pathways
such as those mentioned above.
Conclusions
Our conclusion from this work is that inhibition of ODC
activity and consequent decrease in intracellular pu-
trescine levels does not, per se, constitute a primary mech-
anism of action of I3C in these colon cell lines. However,
perturbation of polyamine homeostasis leading to in-
creases in intracellular spermine levels may contribute to
a cytotoxic effect of the agent. The exact mechanism by
which putrescine sensitised the SW480 cell line to I3C has
not yet been elucidated, and the relevance of this observa-
tion to future chemopreventive strategies involving I3C
remains to be determined.
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